Herpes simplex virus and human papillomavirus genital infections: new and investigational therapeutic options

Viera, Martha H.; Amini, Sadegh; Huo, Ran; Konda, Sailesh; Block, Samantha; Berman, Brian

doi:10.1111/j.1365-4632.2009.04375.x

Cited by 23 publications

(12 citation statements)

References 185 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In cases of drug-resistant herpetic infection, intravenous foscarnet is the agent of choice but carries with it a significant risk of toxicity to the renal tubules. A pyrophosphate analogue that selectively inhibits viral polymerase, foscarnet is primarily used to treat cytomegalovirus when ganciclovir is contraindicated, as well as acyclovir-resistant herpes virus or varicella zoster 1718. Though no adverse events have been reported with foscarnet use in pregnancy, the data are sparse, and current recommendations are for use only in the setting of a high risk of maternal mortality without treatment 19…”

Section: Discussionmentioning

confidence: 99%

Antiviral-Resistant Fulminant Herpes Hepatitis in Pregnancy

2013

View full text Add to dashboard Cite

Fulminant herpes hepatitis with disseminated extrahepatic involvement in pregnancy is rare and carries a high mortality risk. Although acyclovir remains standard first-line therapy, effective management of acyclovir-resistant disseminated herpes simplex virus (HSV) in pregnancy remains elusive. We present a case of disseminated HSV resistant to both acyclovir and foscarnet, the first double-agent resistant case in pregnancy reported in the literature to date. In this case, therapeutic delivery was the ultimate treatment resulting in full recovery.

show abstract

Section: Discussionmentioning

confidence: 99%

Antiviral-Resistant Fulminant Herpes Hepatitis in Pregnancy

2013

View full text Add to dashboard Cite

show abstract

“…Intralesional and systemic interferon have shown efficacy in genital wart clearance, but are not first line given the associated side effects and exorbitant costs [17,23]. Intralesional interferon has demonstrated success rates up to 66% in clinical trials [24].…”

Section: Virucidal Therapymentioning

confidence: 99%

Advancements in Pharmacotherapy for Noncancerous Manifestations of HPV

Kollipara

Ekhlassi

Downing

et al. 2015

JCM

View full text Add to dashboard Cite

Human papillomavirus (HPV) is the most common sexually transmitted disease. Via infection of the basal epithelial cells, HPV causes numerous malignancies and noncancerous cutaneous manifestations. Noncancerous cutaneous manifestations of HPV, including common, plantar, plane, and anogenital warts, are among the most common reasons for an office visit. Although there are various therapies available, they are notoriously difficult to treat. HPV treatments can be grouped into destructive (cantharidin, salicylic acid), virucidal (cidofovir, interferon-α), antimitotic (bleomycin, podophyllotoxin, 5-fluorouracil), immunotherapy (Candida antigen, contact allergen immunotherapy, imiquimod) or miscellaneous (trichloroacetic acid, polyphenon E). The mechanism of action, recent efficacy data, safety profile and recommended regimen for each of these treatment modalities is discussed.

show abstract

“…Herpes infection [10] In herpes virus infections, presently, interferons are considered inferior to antiviral agents due to the lower efficacy, higher cost, and poor tolerability.…”

Section: Genital Wartsmentioning

confidence: 99%